Vaccination with a KBMA Lm targeting a model TAA has also been shown provide comparable anti-tumor efficacy to a live-attenuated Lm strain but with slightly reduced antigen-specific CD8+ T cell responses (Skoberne et al., 2008). Here, CD8A is linked to neoplasm.